tiprankstipranks
United Therapeutics Corp. (DE:UTH)
NASDAQ:UTH
Germany Market
UTH
United Therapeutics
RESEARCH TOOLSreports

United Therapeutics (UTH) Stock Forecast & Price Target

3 Followers
See the Price Targets and Ratings of:

UTH Analyst Ratings

Strong Buy
9Ratings
Strong Buy
7 Buy
2 Hold
0 Sell
Based on 9 analysts giving stock ratings to
United
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

UTH Stock 12 Month Forecast

Average Price Target

€576.30
▲(24.71% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for United Therapeutics in the last 3 months. The average price target is €576.30 with a high forecast of €641.13 and a low forecast of €448.27. The average price target represents a 24.71% change from the last price of €462.10.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"237":"€237","642":"€642","338.25":"€338.3","439.5":"€439.5","540.75":"€540.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":641.13033402,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€641.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":576.30058987875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€576.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":448.26998964,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€448.27</span>\n  </div></div>","useHTML":true}}],"tickPositions":[237,338.25,439.5,540.75,642],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,471.6,484.6407949246154,497.68158984923076,510.72238477384616,523.7631796984615,536.8039746230769,549.8447695476923,562.8855644723077,575.9263593969231,588.9671543215385,602.0079492461539,615.0487441707692,628.0895390953846,{"y":641.13033402,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,471.6,479.6538915291346,487.70778305826923,495.76167458740383,503.8155661165385,511.8694576456731,519.9233491748078,527.9772407039424,536.031132233077,544.0850237622116,552.1389152913462,560.1928068204808,568.2466983496154,{"y":576.30058987875,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,471.6,469.80538381846156,468.0107676369231,466.21615145538465,464.4215352738462,462.62691909230773,460.8323029107693,459.03768672923076,457.2430705476923,455.44845436615384,453.6538381846154,451.8592220030769,450.06460582153846,{"y":448.26998964,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":241.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":238.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":257.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":373.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":392.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":416.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":427.1,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":388.6,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":418.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":516.6,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":485.8,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":474.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":471.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€641.13Average Price Target€576.30Lowest Price Target€448.27
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on DE:UTH
Benjamin Burnett
Wells Fargo
Wells Fargo
€422.21→€641.13
Buy
38.74%
Upside
Reiterated
07/30/26
United Therapeutics (UTHR) Gets a Buy from Wells Fargo
J.P. Morgan Analyst forecast on DE:UTH
Jessica Fye
J.P. Morgan
J.P. Morgan
€596.82
Buy
29.15%
Upside
Reiterated
07/23/26
Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR), Biogen (NASDAQ: BIIB) and Community Health (NYSE: CYH)
Bank of America Securities Analyst forecast on DE:UTH
Jason Gerberry
Bank of America Securities
Bank of America Securities
€538.62→€532.54
Hold
15.24%
Upside
Reiterated
07/10/26
Bank of America Securities Reaffirms Their Hold Rating on United Therapeutics (UTHR)
Jefferies Analyst forecast on DE:UTH
Roger Song
Jefferies
Jefferies
€636.79→€620.28
Buy
34.23%
Upside
Reiterated
07/10/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
RBC Capital Analyst forecast on DE:UTH
Lisa Walter
RBC Capital
RBC Capital
€608.99→€611.59
Buy
32.35%
Upside
Reiterated
07/07/26
RBC Capital Keeps Their Buy Rating on United Therapeutics (UTHR)
Leerink Partners Analyst forecast on DE:UTH
Roanna Ruiz
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
06/29/26
FDA premarket approval of LungFX positive for United Therapeutics, says LeerinkFDA premarket approval of LungFX positive for United Therapeutics, says Leerink
TD Cowen Analyst forecast on DE:UTH
Joseph Thome
TD Cowen
TD Cowen
€573.37→€586.4
Buy
26.90%
Upside
Reiterated
06/05/26
Morgan Stanley Analyst forecast on DE:UTH
Terence Flynn
Morgan Stanley
Morgan Stanley
€448.27
Hold
-2.99%
Downside
Reiterated
06/04/26
Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR), Fate Therapeutics (NASDAQ: FATE) and Edgewise Therapeutics (NASDAQ: EWTX)
H.C. Wainwright Analyst forecast on DE:UTH
Andrew Fein
H.C. Wainwright
H.C. Wainwright
€573.37
Buy
24.08%
Upside
Reiterated
05/29/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Raymond James Analyst forecast on DE:UTH
Tiago Fauth
Raymond James
Raymond James
€608.12
Buy
31.60%
Upside
Initiated
04/09/26
United Therapeutics initiated with an Outperform at Raymond JamesUnited Therapeutics initiated with an Outperform at Raymond James
Cantor Fitzgerald Analyst forecast on DE:UTH
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
€456.09→€542.96
Buy
17.50%
Upside
Initiated
03/12/26
Cantor Fitzgerald Reaffirms Their Buy Rating on United Therapeutics (UTHR)
UBS Analyst forecast on DE:UTH
Ashwani Verma
UBS
UBS
€569.02→€612.46
Buy
32.54%
Upside
Assigned
03/05/26
Analysts Conflicted on These Healthcare Names: Veeva Systems (NYSE: VEEV) and United Therapeutics (NASDAQ: UTHR)
Argus Research Analyst forecast on DE:UTH
Jasper Hellweg
Argus Research
Argus Research
€486.49
Buy
5.28%
Upside
Assigned
03/03/26
United Therapeutics price target raised to $560 from $500 at ArgusUnited Therapeutics price target raised to $560 from $500 at Argus
BTIG Analyst forecast on DE:UTH
Julian Harrison
BTIG
BTIG
―
Hold
―
Reiterated
02/25/26
Balancing Franchise Headwinds and Pipeline Upside: Rationale Behind a Hold on United Therapeutics
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on DE:UTH
Benjamin Burnett
Wells Fargo
Wells Fargo
€422.21→€641.13
Buy
38.74%
Upside
Reiterated
07/30/26
United Therapeutics (UTHR) Gets a Buy from Wells Fargo
J.P. Morgan Analyst forecast on DE:UTH
Jessica Fye
J.P. Morgan
J.P. Morgan
€596.82
Buy
29.15%
Upside
Reiterated
07/23/26
Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR), Biogen (NASDAQ: BIIB) and Community Health (NYSE: CYH)
Bank of America Securities Analyst forecast on DE:UTH
Jason Gerberry
Bank of America Securities
Bank of America Securities
€538.62→€532.54
Hold
15.24%
Upside
Reiterated
07/10/26
Bank of America Securities Reaffirms Their Hold Rating on United Therapeutics (UTHR)
Jefferies Analyst forecast on DE:UTH
Roger Song
Jefferies
Jefferies
€636.79→€620.28
Buy
34.23%
Upside
Reiterated
07/10/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
RBC Capital Analyst forecast on DE:UTH
Lisa Walter
RBC Capital
RBC Capital
€608.99→€611.59
Buy
32.35%
Upside
Reiterated
07/07/26
RBC Capital Keeps Their Buy Rating on United Therapeutics (UTHR)
Leerink Partners Analyst forecast on DE:UTH
Roanna Ruiz
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
06/29/26
FDA premarket approval of LungFX positive for United Therapeutics, says LeerinkFDA premarket approval of LungFX positive for United Therapeutics, says Leerink
TD Cowen Analyst forecast on DE:UTH
Joseph Thome
TD Cowen
TD Cowen
€573.37→€586.4
Buy
26.90%
Upside
Reiterated
06/05/26
Morgan Stanley Analyst forecast on DE:UTH
Terence Flynn
Morgan Stanley
Morgan Stanley
€448.27
Hold
-2.99%
Downside
Reiterated
06/04/26
Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR), Fate Therapeutics (NASDAQ: FATE) and Edgewise Therapeutics (NASDAQ: EWTX)
H.C. Wainwright Analyst forecast on DE:UTH
Andrew Fein
H.C. Wainwright
H.C. Wainwright
€573.37
Buy
24.08%
Upside
Reiterated
05/29/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Raymond James Analyst forecast on DE:UTH
Tiago Fauth
Raymond James
Raymond James
€608.12
Buy
31.60%
Upside
Initiated
04/09/26
United Therapeutics initiated with an Outperform at Raymond JamesUnited Therapeutics initiated with an Outperform at Raymond James
Cantor Fitzgerald Analyst forecast on DE:UTH
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
€456.09→€542.96
Buy
17.50%
Upside
Initiated
03/12/26
Cantor Fitzgerald Reaffirms Their Buy Rating on United Therapeutics (UTHR)
UBS Analyst forecast on DE:UTH
Ashwani Verma
UBS
UBS
€569.02→€612.46
Buy
32.54%
Upside
Assigned
03/05/26
Analysts Conflicted on These Healthcare Names: Veeva Systems (NYSE: VEEV) and United Therapeutics (NASDAQ: UTHR)
Argus Research Analyst forecast on DE:UTH
Jasper Hellweg
Argus Research
Argus Research
€486.49
Buy
5.28%
Upside
Assigned
03/03/26
United Therapeutics price target raised to $560 from $500 at ArgusUnited Therapeutics price target raised to $560 from $500 at Argus
BTIG Analyst forecast on DE:UTH
Julian Harrison
BTIG
BTIG
―
Hold
―
Reiterated
02/25/26
Balancing Franchise Headwinds and Pipeline Upside: Rationale Behind a Hold on United Therapeutics
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
ZURAZura Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering United Therapeutics

3 Months
Roanna RuizLeerink Partners
Success Rate
15/18 ratings generated profit
83%
Average Return
+15.39%
Copying Roanna Ruiz's trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +15.39% per trade.
1 Year
Roger SongJefferies
Success Rate
12/14 ratings generated profit
86%
Average Return
+28.00%
Copying Roger Song's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +28.00% per trade.
2 Years
Ashwani VermaUBS
Success Rate
15/15 ratings generated profit
100%
Average Return
+37.81%
Copying Ashwani Verma's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +37.81% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

UTH Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
22
21
24
15
16
Hold
11
11
9
5
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
33
32
33
20
20
In the current month, UTH has received 16 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. UTH average Analyst price target in the past 3 months is 576.30.
Each month's total comprises the sum of three months' worth of ratings.

UTH Financial Forecast

UTH Earnings Forecast

Next quarter’s earnings estimate for UTH is €5.98 with a range of €5.27 to €7.46. The previous quarter’s EPS was €5.06. UTH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 66.67% of the time in the same period. In the last calendar year UTH has Performed in-line its overall industry.
Next quarter’s earnings estimate for UTH is €5.98 with a range of €5.27 to €7.46. The previous quarter’s EPS was €5.06. UTH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 66.67% of the time in the same period. In the last calendar year UTH has Performed in-line its overall industry.

UTH Sales Forecast

Next quarter’s sales forecast for UTH is €698.91M with a range of €680.11M to €724.40M. The previous quarter’s sales results were €678.80M. UTH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 83.33% of the time in the same period. In the last calendar year UTH has Performed in-line its overall industry.
Next quarter’s sales forecast for UTH is €698.91M with a range of €680.11M to €724.40M. The previous quarter’s sales results were €678.80M. UTH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 83.33% of the time in the same period. In the last calendar year UTH has Performed in-line its overall industry.

UTH Stock Forecast FAQ

What is DE:UTH’s average 12-month price target, according to analysts?
Based on analyst ratings, United Therapeutics Corp.’s 12-month average price target is 576.30.
    What is DE:UTH’s upside potential, based on the analysts’ average price target?
    United Therapeutics Corp. has 24.71% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is United Therapeutics Corp. a Buy, Sell or Hold?
          United Therapeutics Corp. has a consensus rating of Strong Buy, which is based on 7 buy ratings, 2 hold ratings and 0 sell ratings.
            What is United Therapeutics Corp.’s share price target?
            The average share price target for United Therapeutics Corp. is 576.30. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €641.13 ,and the lowest forecast is €448.27. The average share price target represents 24.71% Increase from the current price of €462.1.
              What do analysts say about United Therapeutics Corp.?
              United Therapeutics Corp.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of United Therapeutics Corp.?
                To buy shares of DE:UTH, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.